In Biopharma, No Link Between Size Of Series A And Exit
This article was originally published in Start Up
Executive Summary
Lots of early money, or just a little? In the six years of data we examined, it didn’t matter what a biotech received; there was no correlation to the size of the company’s acquisition price or public market capitalization.